Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NyradaASX:NYR -3.23%18 3-Year EBITDA Growth Rate is 14.90% as of Jun. 2026, which is 107% above its 10-year median of 7.20. GuruFocus rates ASX:NYR with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,122 Biotechnology companies, Nyrada ranks better than 50.18% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nyrada was 14.90% per year. The lowest was -14.00% per year. And the median was 7.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nyrada 3-Year EBITDA Growth Rate Related Terms
ASX:NYR vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Nyrada's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nyrada 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nyrada's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nyrada's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.90% mean?
Nyrada (ASX:NYR) has a 3-Year EBITDA Growth Rate of 14.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nyrada and its competitors. This is 107% above median its historical median of 7.20. According to the industry distribution chart, Nyrada ranks #559 out of 1122 companies in the Biotechnology industry, placing it in the top 49.8%.
Is Nyrada's 3-Year EBITDA Growth Rate too high?
Nyrada's current 3-Year EBITDA Growth Rate of 14.90% is 107% above median its 10-year median of 7.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.75. Nyrada's value of 14.90% is 1% above this industry median. Based on the distribution chart, Nyrada ranks #559 out of 1122 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nyrada has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nyrada ranks #559 out of 1122 companies for 3-Year EBITDA Growth Rate. This puts Nyrada in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.75. Nyrada's value of 14.90% is 1% above this benchmark. While the company's 10-year median is 7.20 vs. the industry median of 14.75, Nyrada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nyrada's current 3-Year EBITDA Growth Rate of 14.90% is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nyrada and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nyrada's current 3-Year EBITDA Growth Rate is 14.90%, which is 107% above median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current 3-Year EBITDA Growth Rate of 14.90%. The current 3-Year EBITDA Growth Rate is 14.90%, which is 107% above median its 10-year median of 7.20 and 1% above the Biotechnology industry median of 14.75. Nyrada's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current 3-Year EBITDA Growth Rate is 14.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
18GF Score
Get the complete analysis for ASX:NYR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NYR has been successfully added to your 
